Predictive Oncology to defend against Renovaro's claims in court

Predictive Oncology (POAI) is set to face Renovaro, Inc. in a Delaware Court of Chancery trial on November 12-13, 2025, after the court denied Renovaro's request for an expedited trial; Predictive Oncology intends to defend against Renovaro's claims, which it deems baseless. Despite recent volatility, POAI stock has gained 25% over the last six months and is considered undervalued by InvestingPro analysis, while analysts project revenue growth of 4.75% for FY2025. The legal dispute follows Predictive Oncology's termination of a planned merger with Renovaro, with Renovaro alleging breach of contract.

Analysis

Predictive Oncology (NASDAQ: POAI) has received a trial date of November 12-13, 2025, for its legal dispute with Renovaro, Inc., following the Delaware Court of Chancery's denial of Renovaro's request for an expedited trial, a decision attributed to Renovaro's delay in initiating action. This development postpones a resolution to the conflict stemming from Predictive Oncology's termination of a planned merger, where Renovaro alleges breach of contract; Predictive Oncology maintains the claims are baseless. Despite this ongoing litigation and recent market volatility, POAI's stock has seen a significant 25% gain over the past six months, trading at $0.98, and is considered undervalued by InvestingPro's Fair Value analysis. The company, specializing in AI-driven drug discovery for cancer, touts its PEDAL platform's 92% predictive accuracy and recent advancements in developing tumor response models for 21 molecules without prior data. Financially, while POAI maintains a solid gross profit margin of 51%, InvestingPro data highlights concerns regarding its cash burn and a 'weak' overall Financial Health Score, even as analysts project a 4.75% revenue growth for FY2025. The extended timeline to trial may afford Predictive Oncology an opportunity to further validate its technology and address its financial challenges.

Key Decisions for Investors

• Investors should weigh Predictive Oncology's undervalued stock and AI technological promise against the significant risks posed by the ongoing litigation with Renovaro, alongside the company's reported cash burn and weak financial health score.
• The November 2025 trial date provides an extended operational runway for POAI; therefore, closely monitoring key milestones in its AI platform development, new partnerships, and any improvements in financial metrics will be critical.
• Given the mixed signals—positive stock momentum and AI potential versus legal uncertainties and financial vulnerabilities—a cautious approach is warranted, possibly involving a limited speculative position for investors with high risk tolerance or deferring investment decisions until more clarity emerges on the legal outcome and financial stability.